Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells
DSpace/Manakin Repository
Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells
| Title: | Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells |
| Author: |
Petrilli, Alejandra M; Garcia, Jeanine; Bott, Marga; Plati, Stephani Klingeman; Dinh, Christine T; Bracho, Olena R; Yan, Denise; Zou, Bing; Mittal, Rahul; Telischi, Fred F; Liu, Xue-Zhong; Chang, Long-Sheng; Bradley, D Welling; Copik, Alicja J; Fernández-Valle, Cristina
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Petrilli, A. M., J. Garcia, M. Bott, S. K. Plati, C. T. Dinh, O. R. Bracho, D. Yan, et al. 2017. “Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.” Oncotarget 8 (19): 31666-31681. doi:10.18632/oncotarget.15912. http://dx.doi.org/10.18632/oncotarget.15912. |
| Full Text & Related Files: |
5458238.pdf (6.676Mb; PDF) 
|
| Abstract: | Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to multiple benign tumors of the central and peripheral nervous systems, including vestibular schwannomas. Currently, there are no FDA approved drug therapies for NF2. Loss of function of merlin encoded by the NF2 tumor suppressor gene leads to activation of multiple mitogenic signaling cascades, including platelet-derived growth factor receptor (PDGFR) and SRC in Schwann cells. The goal of this study was to determine whether ponatinib, an FDA-approved ABL/SRC inhibitor, reduced proliferation and/or survival of merlin-deficient human Schwann cells (HSC). Merlin-deficient HSC had higher levels of phosphorylated PDGFRα/β, and SRC than merlin-expressing HSC. A similar phosphorylation pattern was observed in phospho-protein arrays of human vestibular schwannoma samples compared to normal HSC. Ponatinib reduced merlin-deficient HSC viability in a dose-dependent manner by decreasing phosphorylation of PDGFRα/β, AKT, p70S6K, MEK1/2, ERK1/2 and STAT3. These changes were associated with decreased cyclin D1 and increased p27Kip1levels, leading to a G1 cell-cycle arrest as assessed by Western blotting and flow cytometry. Ponatinib did not modulate ABL, SRC, focal adhesion kinase (FAK), or paxillin phosphorylation levels. These results suggest that ponatinib is a potential therapeutic agent for NF2-associated schwannomas and warrants further in vivo investigation. |
| Published Version: | doi:10.18632/oncotarget.15912 |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458238/pdf/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:33490789 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [20079]
Contact administrator regarding this item (to report mistakes or request changes)
